Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 3, 2000, Pages 316-323

  Pan, Wei Jian ^a   Gustavson, Linda E ^a   Achari, Ramanuj ^a   Rieser, Matthew J ^a   Ye, Xin ^a   Gutterman, Cory ^a   Wallin, Bruce A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; DRUG DERIVATIVE; FENOFIBRATE; FENOFIBRIC ACID; HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG ANTAGONISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; PROCETOFEN;

EID: 0034145932     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008874     Document Type: Article

References (16)

1. Laboratoires Fournier: The Fenafibrate Monograph, Oxford, UK: Oxford Clinical Communications, 1995.
2. Adkins JC, Faulds D: Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997;54:615-633.
3. 14C-fenofibrate in human volunteers. Drug Metab Dispos 1990;18(1):115-120.
4. Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319(1):24-33.
5. Reihnér E, Rudling M, Stáhlberg D, Berglund L, Ewerth S, Björkhem I, Einarsson K, Angelin B: Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990;323(4):224-228.
6. Vanhanen H, Kesäniemi YA, Miettinen TA: Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism 1992;41(6):588-595.
7. Schonfeld G, Aguilar Salina C, Elias N: Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia. Am J Cardiol 1998;81(4A):43B-46B.
8. Quion JA, Jones PH: Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994;27(2):94-103.
9. Desager JP, Horsmans Y: Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996;31(5):348-371.
10. Singhvi SM, Pan HY, Morrison RA, Willard DA: Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990;29(2):239-243.
11. Serajuddin AT, Ranadive SA, Mahoney EM: Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 1991;80(9):830-834.
12. Pan HY, De Vault AR, Brescia D, Willard DA, McGovern ME, Whigan DB, Ivashkiv E: Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993; 31(6):291-294.
13. Everett DW, ChandoTJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH: Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991;19(4):740-748.
14. Lennernäs H, Eager G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997;32(5):403-425.
15. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA: Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990;30(12): 1128-1135.
16. Raslová K, Dubovské D, Mongiellová V, Trnovec T: Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia. Eur J Clin Pharmacol 1997;52(2):101-106.